Nasdaq granted Rosetta Genomics Ltd. an extension to regain compliance with the exchange's listing requirement.

Under the extension, Rosetta Genomics must close its previously announced acquisition by Genoptix Inc. by April 23, 2018.

In case the deal does not go through, the company must raise equity to comply with the exchange's requirement.